Holen Sie sich die Stockscreener-App
32.97
2.46%
0.507
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
Mural Jumps on Partnership with XOMA - Baystreet.ca
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive
Heatmap analysis for XOMA Royalty Corporation and competitorsJuly 2025 Summary & Reliable Volume Spike Alerts - Newser
Mural Oncology to be Acquired by XRA 5 - citybiz
Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP
Xoma adds fading Mural Oncology to portfolio of struggling biotechs - Fierce Biotech
XOMA Royalty To Acquire Mural Oncology - Nasdaq
XOMA Royalty Unit to Acquire Mural Oncology - MarketScreener
XOMA Royalty to acquire Mural Oncology for up to $2.24 per share - Investing.com
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - Yahoo Finance
WALTHAM, DUBLIN, EMERYVILLEMural Oncology agrees to acquisition by XOMA Royalty subsidiary - Investing.com
98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal - Stock Titan
Analyzing drawdowns of XOMA Royalty Corporation with statistical toolsMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Using Bollinger Bands to evaluate XOMA Royalty CorporationShort Setup & AI Enhanced Trade Execution Alerts - Newser
What Fibonacci levels say about XOMA Royalty Corporation reboundQuarterly Market Review & Trade Opportunity Analysis - Newser
What’s next for XOMA Royalty Corporation stock price2025 Big Picture & Free Daily Entry Point Trade Alerts - Newser
Analyzing recovery setups for XOMA Royalty Corporation investorsQuarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
XOMA Royalty Corporation stock retracement – recovery analysisPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Can a trend reversal in XOMA Royalty Corporation lead to recoveryJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - Newser
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% - Yahoo Finance
Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs - Defense World
What institutional flow reveals about XOMA Royalty CorporationWeekly Profit Report & Community Verified Trade Signals - Newser
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
Is XOMA Royalty Corporation stock a buy or sellTrade Entry Summary & Precise Trade Entry Recommendations - thegnnews.com
Leerink Partnrs Forecasts Higher Earnings for XOMA Royalty - Defense World
Custom watchlist performance reports with XOMA Royalty Corporation2025 Risk Factors & Expert Approved Trade Ideas - Newser
What the charts say about XOMA Royalty Corporation today2025 AllTime Highs & Consistent Return Strategy Ideas - Newser
Xoma Completes Merger with Turnstone Biologics Corp - TipRanks
Xoma Corp. Reports Strong Earnings Growth in 2025 - MSN
Xoma: Leerink Partners Reaffirms Buy Rating with $55 Target, Analyst Consensus at Moderate Buy with $62 Average Target - AInvest
We Think XOMA Royalty (NASDAQ:XOMA) Has A Fair Chunk Of Debt - 富途牛牛
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - MarketScreener
Leerink Partners reiterates Outperform rating on XOMA stock amid strong Q2 results - Investing.com Nigeria
XOMA (NASDAQ:XOMAO) Trading Up 0.4% – Here’s Why - Defense World
XOMA Royalty 2025 Q2 Earnings Declining Net Income Amid Revenue Growth - AInvest
Live market analysis of XOMA Royalty CorporationWeekly Risk Summary & Free Daily Entry Point Trade Alerts - Newser
XOMA Royalty Corp Surpasses Revenue Estimates with $13.1M Q2 Revenue, EPS Misses Expectations - AInvest
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - uk.finance.yahoo.com
XOMA Posts 39% Revenue Growth in Q2, Net Income Down 42.5% - AInvest
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
XOMA Royalty Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Will breakout in XOMA Royalty Corporation lead to full recoveryQuarterly Market Review & Weekly Return Optimization Plans - Newser
XOMA Royalty: A Biotech Royalty Aggregator with Explosive Growth Potential - AInvest
XOMA Royalty Corporation Reports Q2 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
Lava Therapeutics shares rise 1.32% intraday after XOMA Royalty Corporation's acquisition of Turnstone Biologics Corp. - AInvest
Should you wait for a breakout in XOMA Royalty CorporationBuy Zone Strategy with Pattern Recognition - Newser
Evaluating XOMA Royalty Corporation with trendline analysisFree Conservative Entry for High Return Setup - Newser
Gold Royalty Corp. shares fall 3.25% intraday after Royalty Management Holding Corporation reported record second quarterly results for the period ended June 30, 2025. - AInvest
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - GlobeNewswire
1.13%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):